MedPath

Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Recruiting
Conditions
Locally Advanced
Urothelial Carcinoma Ureter
Interventions
Procedure: Radical surgery
Radiation: Kidney sparing surgery+Postoperative radiotheray
Registration Number
NCT06120387
Lead Sponsor
Xuesong Li
Brief Summary

In this study, we propose to conduct an ambispective study to analyze the safety of preserved renal unit surgery combined with postoperative adjuvant radiotherapy in patients with limited stage ureteral cancer with high risk factors, and the efficacy analysis compared with traditional radical surgery. It is hoped that a treatment method that preserves patients' renal function to improve the tolerance of subsequent drug therapy without decreasing the effect of tumor treatment can be achieved in patients with high-risk factors.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria
    1. Ureteral cancer patients with high-risk factors (high-risk factors define multifocal; G3; T2-4); surgery may be performed with patients undergoing partial terminal ureteral resection or radical nephroureterectomy 2)Age ≥18 years; 3)Completion of abdominopelvic CT 4 weeks before enrollment to exclude distant metastasis and regional lymph node metastasis.
  1. Patients did not have other malignant neoplastic diseases in the last 5 years except for non-melanoma of the skin and ductal carcinoma in situ of the breast; Willing to participate in perfecting the necessary examinations and follow-up for the sake of the study, and willing to provide written informed consent.
Exclusion Criteria
    1. Distant metastasis or retroperitoneal lymph node metastasis (N+) had been detected at the time of surgery; R2 resection patients; history of bladder cancer; 2) History of pelvic and abdominal radiotherapy; history of inflammatory bowel disease; history of systemic chemotherapy; 3) Pregnant women or breastfeeding women; or women of childbearing potential who are not practicing reliable contraception; (4) The presence of active infections in those with pre-existing or coexisting bleeding disorders 5) clinically significant cardiac disease (e.g., hypertension controlled with medications, unstable angina, New York Heart Association (NYHA) class ≥II congestive heart failure, unstable symptomatic arrhythmias, or class ≥II peripheral vascular disease); 6) Psychological, family, and social factors leading to lack of informed consent.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Radical surgery cohortRadical surgeryPreoperative CT/MRI, chest CT and other examinations are performed to determine the stage of the patient's disease. The surgical plan is the same as the current conventional treatment. After surgery, there is no restriction on the use of postoperative adjuvant chemotherapy or postoperative adjuvant radiotherapy according to the patient's pathological stage and the patient's wish.
Kidney sparing surgery+Postoperative radiotheray cohortKidney sparing surgery+Postoperative radiotherayKidney sparing surgery+Postoperative radiotheray cohort
Primary Outcome Measures
NameTimeMethod
Renal Function IndicatorsPerioperation and peri-treatment

eGFR, Crea

Local recurrence free survival (LRFS)1-year, 3-year and 5-year

Local recurrence

Secondary Outcome Measures
NameTimeMethod
Overall survival (OS)1-year, 3-year and 5-year

Overall survival

Adverse effects (AE)Perioperation and peri-treatment

Adverse effects

Intravesical and contralateral recurrence free survival(IRFS and CRFS)1-year, 3-year and 5-year

Intravesical and contralateral recurrence free survival

Metastasis free survival (MFS)1-year, 3-year and 5-year

Distant metastasis

Trial Locations

Locations (2)

Departmeng of Urology, Peking University First Hospital

🇨🇳

Beijing, China

Department of Radiotherapy Oncology, Peking University First Hospital

🇨🇳

Beijing, China

© Copyright 2025. All Rights Reserved by MedPath